The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Mutations in this gene have been associated with the Proteus syndrome. Multiple alternatively spliced transcript variants have been found for this gene.
維真生物的產品僅限用于研究,不可用于包括人類體外診斷和治療在內的其他用途。
維真生物的產品,不得修改和轉售給任何第三方,未經維真生物的書面批準,不得將產品用于向其他第三方提供服務或用于制造商品化產品。
使用本產品應遵守以上條款以及網站//www.vigenebio.cn上的產品相關規定。您有責任閱讀、了解并遵守這些條款所產生的任何限制。